CN1424112A - Water soluble dressing for insoluble medicines and preparation thereof - Google Patents
Water soluble dressing for insoluble medicines and preparation thereof Download PDFInfo
- Publication number
- CN1424112A CN1424112A CN 02155140 CN02155140A CN1424112A CN 1424112 A CN1424112 A CN 1424112A CN 02155140 CN02155140 CN 02155140 CN 02155140 A CN02155140 A CN 02155140A CN 1424112 A CN1424112 A CN 1424112A
- Authority
- CN
- China
- Prior art keywords
- clathrate
- derivant
- class
- water
- insoluble drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A water-soluble inclusion compound of the medicine difficult to dissolve is prepared from said medicine difficult to dissolve and the cyclodextrin derivative through adding said medicine to the solution of cyclodextrin in organic solvent, thermal refluxing until the medicine is fully dissolved, and volatilizing the organic solvent. Its advantages are short period (1-2) hr and wide range of medicines.
Description
Technical field
The present invention relates to water solublity clathrate of insoluble drug and preparation method thereof.
Background technology
The bioavailability of insoluble drug such as alkaloids, lignan's class, flavonoids class, triterpenoid, diterpene compound class, sesquiterpenoid, monoterpene class and glycoside is lower usually, so usually need improve their water solublity, the means of employing have: salify, micronization, emulsifying, make solid dispersion or clathrate etc.Clathrate refers to goes into the inside of water-solubility carrier molecule with pharmaceutical pack (its preparation method is gone into pharmaceutical pack the inside of water soluble molecules usually, forms a kind of clathrate, and is simple and effective, and the medicine of technology preparation and the complex of water-solubility carrier are claimed clathrate thus.) cyclodextrin and derivant thereof be exactly class enclose carrier of normal use of preparation clathrate.
At present, the Chang Yong method for preparing drug-cyclodextrin or derivatives thereof clathrate has: saturated water solution method, supercritical ultrasonics technology, polishing, freeze-drying, spray drying method and solution-paddling process etc.Their shortcoming is: length consuming time, be not suitable for the medicine of water solublity extreme difference.
Summary of the invention
The technical issues that need to address of the present invention provide water solublity clathrate of a kind of insoluble drug and preparation method thereof, to overcome the length consuming time that prior art exists, the defective that is not suitable for the medicine of water solublity extreme difference.
The water solublity clathrate of insoluble drug of the present invention is a kind of compositions, is made of the insoluble drug and the cyclodextrin derivative for the treatment of effective dose, and its preferred ingredients and content are: the mol ratio of insoluble drug and cyclodextrin derivative is: 0.1～100: 1.
Said clathrate contains half or a plurality of water of crystallization or do not contain water of crystallization.
The final application form of this clathrate can be aqueous solution, lyophilized preparation, tablet, capsule, granule, soft gelatin capsule, suction powder, suppository etc.
Said insoluble drug is included in dissolubility in the water less than 1% medicine.
Insoluble drug commonly used comprises:
Alkaloids is as alkaloid and derivants thereof such as berberine, ephedrine, coptisine, corydaline, ipecine, physostigmine, atropina, 2.beta.-carbomethoxy-3.beta.-benzoxytropane, codeine, morphine, quinine, homoharringtonine, camptothecine, papaverine, atropine, hyoscyamine, matrine, aconitine, vinblastine, reserpine, Rhizoma Chuanxiong alkali, dauricine, anabasine, tetrandrine, ergotin, pilocarpine, theophylline, Securinine, colchicine or orixines;
Lignan's class is as lignan and derivants thereof such as podophyllotoxin, schizantherin, guaiaconic acids;
The flavonoids class is as flavonoids and derivants thereof such as silymarin, puerarins;
The triterpenoid class is as triterpenoid and derivants thereof such as oleanolic acid;
The diterpene compound class is as diterpene compound and derivants thereof such as bilobalide, TANSHINONES, andrographolide, Triptolide, plectranthin, Cortex Pseudolaricis acid, paclitaxels;
The sesquiterpenoid class is as sesquiterpenoid and derivants thereof such as arteannuin;
The monoterpene class is as monoterpene and derivants thereof such as curcumenol, pyrethrins;
Glycoside is as glycoside and derivants thereof such as baicalin, psoralen, chrysophanic acid, the fragrant glycoside of cloud, aesculetin, digitophyllin, digoxin, convallatoxins.
Said cyclodextrin derivative comprises: the alpha-cyclodextrin derivant of various substitution values, beta-cyclodextrin derivative, gamma-cyclodextrin derivant, best choice are one or more in HP-, the sulfobutyl ether-beta-cyclodextrin etc.
The using method of clathrate of the present invention is identical with using dosage and routine, and the relevant personnel can be according to patient's the state of an illness and the patient that practical situation is implemented and needs are treated.
Method of the present invention comprises the steps:
Insoluble drug is put in the organic solvent of cyclodextrin derivative, reflux to medicine dissolves fully, flings to organic solvent, promptly obtains water miscible clathrate.
Said non-water-soluble matchmaker includes but not limited to: one or more in ethanol, methanol, acetonitrile, acetone, isopropyl alcohol, n-butyl alcohol, the oxolane etc.
Because insoluble drug and the cyclodextrin derivative addressed can be dissolved in the organic solvent under reflux state quickly, general dissolution time is 1～2 hour, therefore, can shorten preparation time greatly, making simultaneously originally can't also can be by solubilising by the medicine of cyclodextrin or derivatives thereof enclose.
This shows that the preparation time of clathrate of the present invention shortens greatly, shorten to 1～2 hour from original a couple of days, enlarged the medicine scope that is suitable for simultaneously, be a kind of technology of water solublity clathrate of the preparation insoluble drug that the industrial applications prospect arranged.
The specific embodiment
Embodiment 1
1 gram berberine and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 2 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 2
1 gram schisantherin A and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 1.5 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 3
1 gram silymarin and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 1 hour to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 4
1 gram oleanolic acid and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 2 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 5
1 gram bilobalide and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 2 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 6
1 gram arteannuin and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 2 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 7
1 gram curcumenol and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000m1 dehydrated alcohol, all dissolve in 80 ℃ of reflux 2 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Embodiment 8
1 gram baicalin and number gram HP-(or number gram sulfobutyl ether-beta-cyclodextrin) is mixed with the 1000ml dehydrated alcohol, all dissolve in 80 ℃ of reflux 2 hours to medicine.Be evaporated to constant weight, obtain clathrate.
Claims (10)
1. the water solublity clathrate of insoluble drug is characterized in that being made of the insoluble drug and the cyclodextrin derivative of treatment effective dose.
2. clathrate according to claim 1 is characterized in that, the mol ratio of insoluble drug and cyclodextrin derivative is: 0.1～100: 1, contain half or a plurality of water of crystallization or do not contain water of crystallization.
3. clathrate according to claim 1 is characterized in that, the final application form of clathrate includes but not limited to: aqueous solution, lyophilized preparation, tablet, capsule, granule, soft gelatin capsule, suppository or suction powder.
4. clathrate according to claim 1 is characterized in that, said insoluble drug comprises that dissolubility in the water is less than 1% medicine.
5. clathrate according to claim 2 is characterized in that, said insoluble drug comprises that dissolubility in the water is less than 1% medicine.
6. clathrate according to claim 3 is characterized in that, said insoluble drug comprises that dissolubility in the water is less than 1% medicine.
7. according to each described clathrate of claim 1～6, it is characterized in that, insoluble drug comprises: a kind of in alkaloids, lignan's class, flavonoids class, triterpenoid class, diterpene compound class, sesquiterpenoid class, monoterpene class or the glycoside, said cyclodextrin derivative comprises one or more in alpha-cyclodextrin derivant, beta-cyclodextrin derivative, gamma-cyclodextrin derivant of various substitution values etc., comprises HP-, sulfobutyl ether-beta-cyclodextrin.
8. clathrate according to claim 7 is characterized in that, described medicine is:
Alkaloids comprises berberine, ephedrine, coptisine, corydaline, ipecine, physostigmine, atropina, 2.beta.-carbomethoxy-3.beta.-benzoxytropane, codeine, morphine, quinine, homoharringtonine, camptothecine, papaverine, atropine, hyoscyamine, matrine, aconitine, vinblastine, reserpine, Rhizoma Chuanxiong alkali, dauricine, anabasine, tetrandrine, ergotin, pilocarpine, theophylline, Securinine, colchicine or orixine and derivant thereof;
Lignan's class comprises podophyllotoxin, schizantherin, guaiaconic acid and derivant thereof;
The flavonoids class comprises silymarin, puerarin and derivant thereof;
Triterpenoid comprises oleanolic acid and derivant thereof;
Diterpene compound comprises bilobalide, TANSHINONES, andrographolide, Triptolide, plectranthin, Cortex Pseudolaricis acid or paclitaxel and derivant thereof;
Sesquiterpenoid comprises arteannuin and derivant thereof;
Monoterpene comprises curcumenol or pyrethrin and derivant thereof;
Glycoside comprises baicalin, psoralen, chrysophanic acid, the fragrant glycoside of cloud, aesculetin, digitophyllin, digoxin, convallatoxin and derivant thereof.
9. according to the preparation method of each said clathrate of claim 1～8, it is characterized in that comprising the steps:
Insoluble drug is put in the organic solvent of cyclodextrin derivative, reflux to medicine dissolves fully, flings to organic solvent, promptly obtains water miscible clathrate.
10. preparation method according to claim 9 is characterized in that said non-water-soluble matchmaker includes but not limited to: one or more in ethanol, methanol, acetonitrile, acetone, isopropyl alcohol, n-butyl alcohol or the oxolane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02155140 CN1424112A (en) | 2002-12-17 | 2002-12-17 | Water soluble dressing for insoluble medicines and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02155140 CN1424112A (en) | 2002-12-17 | 2002-12-17 | Water soluble dressing for insoluble medicines and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1424112A true CN1424112A (en) | 2003-06-18 |
Family
ID=4752572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02155140 Pending CN1424112A (en) | 2002-12-17 | 2002-12-17 | Water soluble dressing for insoluble medicines and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1424112A (en) |
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008031286A1 (en) * | 2006-09-12 | 2008-03-20 | Nanjing Normal University | Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof |
| CN100594940C (en) * | 2007-08-08 | 2010-03-24 | 昆明制药集团股份有限公司 | Supermolecule water soluble freeze drying matter of indissoluble medicament and method of preparing the same |
| WO2010054507A1 (en) * | 2008-11-11 | 2010-05-20 | 石药集团中奇制药技术（石家庄）有限公司 | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives |
| CN101250288B (en) * | 2008-01-18 | 2010-06-02 | 南通大学 | Cyclovirobuxine D cyclodextrin or cyclodextrin derivative clathrate compound and preparation method thereof |
| CN1919240B (en) * | 2005-08-24 | 2011-02-16 | 天津天士力制药股份有限公司 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases |
| CN1919243B (en) * | 2005-08-24 | 2011-03-23 | 天津天士力制药股份有限公司 | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases |
| CN101991856A (en) * | 2010-11-05 | 2011-03-30 | 北京工业大学 | Preparation method of water-soluble inclusion compound of slightly soluble drug |
| WO2011044824A1 (en) * | 2009-10-15 | 2011-04-21 | 中国药科大学 | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof |
| CN102228506A (en) * | 2011-06-16 | 2011-11-02 | 天津中医药大学 | Composition of malaytea scurfpea extract as well as preparation method and use thereof |
| CN102266568A (en) * | 2011-08-01 | 2011-12-07 | 扬州大学 | Preparation method for hydroxypropyl cyclodextrin inclusion of taxol |
| CN102380104A (en) * | 2011-11-07 | 2012-03-21 | 吴葆金 | Preparation method of deoxypodophyllotoxin-hydroxypropyl beta-cyclodextrin clathrate compound |
| CN102406635A (en) * | 2011-10-31 | 2012-04-11 | 栗进才 | Medicine containing diacetyl rheinic acid compound and method for preparing clathrate compound of diacetyl rheinic acid compound |
| CN102428181A (en) * | 2009-05-19 | 2012-04-25 | 三得利控股株式会社 | Glucosyltransferase Specific To Position-4 Of Furofuran-Type Lignan, And Polynucleotide Encoding Same |
| CN102933235A (en) * | 2010-01-14 | 2013-02-13 | 沙皮奥泰克有限责任公司 | Halogenated ether complex |
| CN103099803A (en) * | 2011-11-10 | 2013-05-15 | 复旦大学 | Method for solubilization and synchronous dissolution of bilobalide |
| CN103142945A (en) * | 2013-04-05 | 2013-06-12 | 李宝 | Tear gas cleaning agent |
| CN103142499A (en) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | Etoposide particle |
| US8481511B2 (en) | 2006-09-12 | 2013-07-09 | Hainan Hdeton Science and Technology Co., Ltd. | Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
| CN102046183B (en) * | 2008-06-17 | 2013-11-13 | 伊莱亚斯·布拉斯 | Compositions for the treatment of hair loss |
| CN104222081A (en) * | 2014-06-27 | 2014-12-24 | 中国人民解放军第三军医大学第一附属医院 | Ethylparaben and hydroxypropyl-beta-cyclodextrin supermolecular inclusion complex and preparation method and using method of inclusion complex |
| CN104587412A (en) * | 2015-02-11 | 2015-05-06 | 李宝 | Mouth mucosa patch for treating tracheospasm |
| CN104826123A (en) * | 2015-04-10 | 2015-08-12 | 昆明理工大学 | Clathrate compound of oleanolic acid and amine cyclodextrin |
| CN104955330A (en) * | 2012-09-13 | 2015-09-30 | Cba制药有限公司 | Tetrandrine pharmaceutical formulations and method |
| CN105412035A (en) * | 2015-12-10 | 2016-03-23 | 昆药集团股份有限公司 | Colchicine sublingual tablet, preparation method and application thereof |
| CN105726529A (en) * | 2016-02-18 | 2016-07-06 | 云南民族大学 | Water-soluble drug dracaena fragrans compound and preparing method thereof |
| CN105816422A (en) * | 2015-01-05 | 2016-08-03 | 天士力制药集团股份有限公司 | Silibinin injection and preparation method thereof |
| WO2016149685A1 (en) * | 2015-03-19 | 2016-09-22 | Cydex Pharmaceuticals, Inc. | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same |
| CN106265567A (en) * | 2016-08-30 | 2017-01-04 | 林州中农颖泰生物肽有限公司 | A kind of water solublity aminophylline tablets and preparation method thereof |
| CN106614665A (en) * | 2016-11-13 | 2017-05-10 | 徐州得铸生物科技有限公司 | A pesticide composition containing convallatoxin |
| CN106667906A (en) * | 2017-03-22 | 2017-05-17 | 中国人民解放军第三军医大学第二附属医院 | Coptisine injection as well as preparation method and application thereof |
| CN106943605A (en) * | 2017-05-08 | 2017-07-14 | 重庆植恩药业有限公司 | Orlistat inclusion compound and preparation method thereof and the application in antineoplastic |
| CN107260694A (en) * | 2017-06-14 | 2017-10-20 | 广西大海阳光药业有限公司 | One kind treats silicosis, rheumatalgia, arthralgia and neuralgic long-acting novel formulation |
| CN107736345A (en) * | 2017-10-17 | 2018-02-27 | 天津农学院 | A kind of composition of medicine for having selectively killing Microcystis aeruginosa and promoting to grow beneficial to swim alga |
| CN107773763A (en) * | 2016-08-25 | 2018-03-09 | 江苏康缘药业股份有限公司 | Bilobalide K beta cyclodextrin clathrate and preparation method thereof |
| CN107982212A (en) * | 2017-11-28 | 2018-05-04 | 杭州赫尔斯科技有限公司 | A kind of atropic category medicament slow release eye drops and preparation method thereof |
| CN108338969A (en) * | 2018-02-08 | 2018-07-31 | 胡敏 | A kind of low concentration tropane class drug eye drops and preparation method thereof |
| CN110507698A (en) * | 2019-09-04 | 2019-11-29 | 淮北师范大学 | A kind of agent of common rabdosia leaf extract particles and preparation method of anti-mycobacterium tuberculosis |
| CN112190498A (en) * | 2020-10-31 | 2021-01-08 | 华南理工大学 | Water-soluble theophylline and cyclodextrin inclusion compound and preparation method thereof |
-
2002
- 2002-12-17 CN CN 02155140 patent/CN1424112A/en active Pending
Cited By (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919240B (en) * | 2005-08-24 | 2011-02-16 | 天津天士力制药股份有限公司 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases |
| CN1919243B (en) * | 2005-08-24 | 2011-03-23 | 天津天士力制药股份有限公司 | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases |
| US8481511B2 (en) | 2006-09-12 | 2013-07-09 | Hainan Hdeton Science and Technology Co., Ltd. | Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process |
| US8426385B2 (en) | 2006-09-12 | 2013-04-23 | Hainan Hdeton Science And Technology Co. Ltd. | Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof |
| WO2008031286A1 (en) * | 2006-09-12 | 2008-03-20 | Nanjing Normal University | Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof |
| CN100594940C (en) * | 2007-08-08 | 2010-03-24 | 昆明制药集团股份有限公司 | Supermolecule water soluble freeze drying matter of indissoluble medicament and method of preparing the same |
| CN101250288B (en) * | 2008-01-18 | 2010-06-02 | 南通大学 | Cyclovirobuxine D cyclodextrin or cyclodextrin derivative clathrate compound and preparation method thereof |
| CN102046183B (en) * | 2008-06-17 | 2013-11-13 | 伊莱亚斯·布拉斯 | Compositions for the treatment of hair loss |
| US9949946B2 (en) | 2008-11-11 | 2018-04-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives |
| EA020784B1 (en) * | 2008-11-11 | 2015-01-30 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКЛ ТЕКНОЛОДЖИ (ШИЦЯЧЖУАН) КО., ЛТД. | Inclusion complexes of pinocembrin with cyclodextrin, process for preparing and use thereof |
| WO2010054507A1 (en) * | 2008-11-11 | 2010-05-20 | 石药集团中奇制药技术（石家庄）有限公司 | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives |
| CN102428181A (en) * | 2009-05-19 | 2012-04-25 | 三得利控股株式会社 | Glucosyltransferase Specific To Position-4 Of Furofuran-Type Lignan, And Polynucleotide Encoding Same |
| WO2011044824A1 (en) * | 2009-10-15 | 2011-04-21 | 中国药科大学 | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof |
| JP2013507401A (en) * | 2009-10-15 | 2013-03-04 | ジェージァン ジェンフォン ファーマシューティカル ホールディングス | Cyclodextrin deoxypodophyllotoxin inclusion complex, its preparation, and use in cancer treatment |
| US8859527B2 (en) | 2009-10-15 | 2014-10-14 | Zhejiang Jianfeng Pharmaceutical Holdings | Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof |
| CN102933235B (en) * | 2010-01-14 | 2015-11-25 | 沙皮奥泰克有限责任公司 | Fluorine ether (Fluran) complex |
| CN102933235A (en) * | 2010-01-14 | 2013-02-13 | 沙皮奥泰克有限责任公司 | Halogenated ether complex |
| CN101991856B (en) * | 2010-11-05 | 2012-06-20 | 北京工业大学 | Preparation method of water-soluble inclusion compound of slightly soluble drug |
| CN101991856A (en) * | 2010-11-05 | 2011-03-30 | 北京工业大学 | Preparation method of water-soluble inclusion compound of slightly soluble drug |
| CN102228506A (en) * | 2011-06-16 | 2011-11-02 | 天津中医药大学 | Composition of malaytea scurfpea extract as well as preparation method and use thereof |
| CN102266568A (en) * | 2011-08-01 | 2011-12-07 | 扬州大学 | Preparation method for hydroxypropyl cyclodextrin inclusion of taxol |
| CN102406635A (en) * | 2011-10-31 | 2012-04-11 | 栗进才 | Medicine containing diacetyl rheinic acid compound and method for preparing clathrate compound of diacetyl rheinic acid compound |
| CN102380104A (en) * | 2011-11-07 | 2012-03-21 | 吴葆金 | Preparation method of deoxypodophyllotoxin-hydroxypropyl beta-cyclodextrin clathrate compound |
| CN103099803A (en) * | 2011-11-10 | 2013-05-15 | 复旦大学 | Method for solubilization and synchronous dissolution of bilobalide |
| CN103099803B (en) * | 2011-11-10 | 2014-10-29 | 复旦大学 | Method for solubilization and synchronous dissolution of bilobalide |
| CN104955330A (en) * | 2012-09-13 | 2015-09-30 | Cba制药有限公司 | Tetrandrine pharmaceutical formulations and method |
| CN103142499A (en) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | Etoposide particle |
| CN103142499B (en) * | 2013-03-21 | 2014-10-01 | 青岛正大海尔制药有限公司 | Etoposide particle |
| CN103142945A (en) * | 2013-04-05 | 2013-06-12 | 李宝 | Tear gas cleaning agent |
| CN104222081A (en) * | 2014-06-27 | 2014-12-24 | 中国人民解放军第三军医大学第一附属医院 | Ethylparaben and hydroxypropyl-beta-cyclodextrin supermolecular inclusion complex and preparation method and using method of inclusion complex |
| CN105816422B (en) * | 2015-01-05 | 2020-08-14 | 天士力医药集团股份有限公司 | Silibinin injection and preparation method thereof |
| CN105816422A (en) * | 2015-01-05 | 2016-08-03 | 天士力制药集团股份有限公司 | Silibinin injection and preparation method thereof |
| CN104587412A (en) * | 2015-02-11 | 2015-05-06 | 李宝 | Mouth mucosa patch for treating tracheospasm |
| WO2016149685A1 (en) * | 2015-03-19 | 2016-09-22 | Cydex Pharmaceuticals, Inc. | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same |
| CN108348560A (en) * | 2015-03-19 | 2018-07-31 | 锡德克斯药物公司 | Include the composition and its application method of silymarin and sulphur hydrocarbyl ether cyclodextrin |
| JP2021143210A (en) * | 2015-03-19 | 2021-09-24 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Composition containing silymarin and sulfoalkyl ether cyclodextrin, and method of using the same |
| EP3939582A1 (en) * | 2015-03-19 | 2022-01-19 | Cydex Pharmaceuticals, Inc. | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same |
| JP7239640B2 (en) | 2015-03-19 | 2023-03-14 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Compositions Containing Silymarin and Sulfoalkyl Ether Cyclodextrins and Methods of Using The Same |
| US11382944B2 (en) | 2015-03-19 | 2022-07-12 | Cydex Pharmaceuticals, Inc. | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same |
| JP2018510220A (en) * | 2015-03-19 | 2018-04-12 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | Compositions containing silymarin and sulfoalkyl ether cyclodextrins and methods of using the same |
| CN104826123B (en) * | 2015-04-10 | 2017-11-10 | 昆明理工大学 | A kind of inclusion compound of oleanolic acid and amine cyclodextrin |
| CN104826123A (en) * | 2015-04-10 | 2015-08-12 | 昆明理工大学 | Clathrate compound of oleanolic acid and amine cyclodextrin |
| CN105412035A (en) * | 2015-12-10 | 2016-03-23 | 昆药集团股份有限公司 | Colchicine sublingual tablet, preparation method and application thereof |
| CN105726529A (en) * | 2016-02-18 | 2016-07-06 | 云南民族大学 | Water-soluble drug dracaena fragrans compound and preparing method thereof |
| CN107773763A (en) * | 2016-08-25 | 2018-03-09 | 江苏康缘药业股份有限公司 | Bilobalide K beta cyclodextrin clathrate and preparation method thereof |
| CN106265567A (en) * | 2016-08-30 | 2017-01-04 | 林州中农颖泰生物肽有限公司 | A kind of water solublity aminophylline tablets and preparation method thereof |
| CN106614665A (en) * | 2016-11-13 | 2017-05-10 | 徐州得铸生物科技有限公司 | A pesticide composition containing convallatoxin |
| CN106667906A (en) * | 2017-03-22 | 2017-05-17 | 中国人民解放军第三军医大学第二附属医院 | Coptisine injection as well as preparation method and application thereof |
| CN106943605A (en) * | 2017-05-08 | 2017-07-14 | 重庆植恩药业有限公司 | Orlistat inclusion compound and preparation method thereof and the application in antineoplastic |
| CN107260694A (en) * | 2017-06-14 | 2017-10-20 | 广西大海阳光药业有限公司 | One kind treats silicosis, rheumatalgia, arthralgia and neuralgic long-acting novel formulation |
| CN107736345A (en) * | 2017-10-17 | 2018-02-27 | 天津农学院 | A kind of composition of medicine for having selectively killing Microcystis aeruginosa and promoting to grow beneficial to swim alga |
| CN107982212A (en) * | 2017-11-28 | 2018-05-04 | 杭州赫尔斯科技有限公司 | A kind of atropic category medicament slow release eye drops and preparation method thereof |
| CN108338969A (en) * | 2018-02-08 | 2018-07-31 | 胡敏 | A kind of low concentration tropane class drug eye drops and preparation method thereof |
| CN110507698A (en) * | 2019-09-04 | 2019-11-29 | 淮北师范大学 | A kind of agent of common rabdosia leaf extract particles and preparation method of anti-mycobacterium tuberculosis |
| CN112190498A (en) * | 2020-10-31 | 2021-01-08 | 华南理工大学 | Water-soluble theophylline and cyclodextrin inclusion compound and preparation method thereof |
| CN112190498B (en) * | 2020-10-31 | 2022-03-25 | 华南理工大学 | Water-soluble theophylline and cyclodextrin inclusion compound and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1424112A (en) | Water soluble dressing for insoluble medicines and preparation thereof | |
| KR950008764B1 (en) | Sustained release drug preparation | |
| CN100478016C (en) | Sarcandra solid dispersion and its preparing method | |
| JP4378755B2 (en) | Inclusion complexes of butylphthalide and cyclodextrin or derivatives thereof, processes for their preparation and use thereof | |
| CN103800916A (en) | Glucan inclusion compound of water-insoluble small molecule drug and preparation method thereof | |
| Granados et al. | Application of hot-melt extrusion in the complexation of naringenin with cyclodextrin using hydrophilic polymers | |
| CN102871950A (en) | Ursolic acid solid dispersion and preparation method thereof | |
| CN110960491B (en) | Preparation method and application of tanshinone IIA-loaded water-soluble chitosan/gamma-polyglutamic acid nano-composite | |
| CN1410068A (en) | Preparation method of water soluble tanshinone | |
| CN109602724B (en) | Oral nanometer preparation of arctigenin and preparation method thereof | |
| Sher et al. | Formulation and Evaluation of Hydroxypropylmethylcellulose-dicyclomine Microsponges for Colon Targeted Drug Delivery: In Vitro and In Vivo Evaluation | |
| CN1366933A (en) | Nano Qiyeshen'an preparation medicine and preparation method | |
| Chen et al. | A comparative study on the preparation and evaluation of solubilizing systems for silymarin | |
| CN1368127A (en) | Nano medicine 'Liandanxiaoyan' and its preparing process | |
| BG4347U1 (en) | Silymarin-based colloidal aqueous system | |
| CN1368122A (en) | Nano antivirus medicine and its preparing process | |
| CN1368225A (en) | Nano medicine 'Beimuerdong' and its preparing process | |
| CN1364517A (en) | Nano stringy stonecrop medicine and its preparing method | |
| CN1365773A (en) | Nano medicine 'Niuhuang Qianjin' and its preparing process | |
| CN1364606A (en) | Nano compound loquat leaf medicine and its preparing method | |
| CN1360932A (en) | Nanometer breast nodule-eliminating medicine and its prepn | |
| CN1360940A (en) | Nanometer psoriasis-treating medicine and its prepn | |
| CN1368124A (en) | Nano medicine for treating stomatitis and its preparing process | |
| CN1368210A (en) | Nano medicine 'Chuanbeili' and its preparing process | |
| CN1364491A (en) | Nano twelve imgredient hooker winghead root medicine and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |